OTLK Outlook Therapeutics Inc
Price (delayed)
$1.25
Market cap
$40.02M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.62
Enterprise value
$65.35M
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME
Highlights
The net income has grown by 38% from the previous quarter and by 9% YoY
Outlook Therapeutics's equity has shrunk by 107% YoY but it has increased by 31% QoQ
OTLK's debt is down by 15% year-on-year but it is up by 4.3% since the previous quarter
The quick ratio has dropped by 66% since the previous quarter and by 48% year-on-year
The EPS has contracted by 16% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of OTLK
Market
Valuations
Earnings
Shares outstanding
32.02M
Market cap
$40.02M
Enterprise value
$65.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$82.99M
Net income
-$46.81M
EBIT
-$43.72M
EBITDA
-$43.61M
Free cash flow
-$66.73M
Per share
Balance sheet
Liquidity
EPS
-$4.62
EPS diluted
-$7.42
Free cash flow per share
-$2.75
Book value per share
-$2.02
Revenue per share
$0
TBVPS
$0.7
Total assets
$17.01M
Total liabilities
$67.3M
Debt
$31.03M
Equity
-$50.29M
Working capital
-$32.57M
Debt to equity
-0.62
Current ratio
0.32
Quick ratio
0.12
Net debt/EBITDA
-0.58
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-123.2%
Return on equity
N/A
Return on invested capital
-6,077.6%
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OTLK stock price
How has the Outlook Therapeutics stock price performed over time
Intraday
2.46%
1 week
-3.1%
1 month
-16.67%
1 year
-87.11%
YTD
-33.86%
QTD
2.46%
Financial performance
How have Outlook Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$82.99M
Net income
-$46.81M
Gross margin
N/A
Net margin
N/A
OTLK's operating income has shrunk by 74% YoY and by 16% QoQ
The net income has grown by 38% from the previous quarter and by 9% YoY
Growth
What is Outlook Therapeutics's growth rate over time
Valuation
What is Outlook Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 16% YoY and by 14% from the previous quarter
Outlook Therapeutics's equity has shrunk by 107% YoY but it has increased by 31% QoQ
Efficiency
How efficient is Outlook Therapeutics business performance
OTLK's return on invested capital has dropped by 125% since the previous quarter
The company's return on assets rose by 36% QoQ and by 9% YoY
Dividends
What is OTLK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OTLK.
Financial health
How did Outlook Therapeutics financials performed over time
OTLK's total assets is 75% smaller than its total liabilities
The quick ratio has dropped by 66% since the previous quarter and by 48% year-on-year
The current ratio has plunged by 50% from the previous quarter and by 27% YoY
OTLK's debt is 162% greater than its equity
Outlook Therapeutics's equity has shrunk by 107% YoY but it has increased by 31% QoQ
OTLK's debt to equity has surged by 59% year-on-year but it has dropped by 51% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.